Corcept Therapeutics News and Activities

Corcept Therapeutics is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Corcept Therapeutics is a company listed under the stock ticker CORT (US).

View the org chart displaying its 33 main executives

Most searched biographies at Corcept Therapeutics

• Joseph Belanoff, Chief Executive Officer & Director
• Joshua Murray, Director
• Daniel Swisher, Director

Popular executive movements at Corcept Therapeutics

• Gillian Cannon, Director, has left the company  (posted on October 8 2025).

Create your alert
to follow the executive moves at Corcept Therapeutics.

Corcept Therapeutics has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Corcept Therapeutics

• Press Releases – Corcept Therapeutics, Incorporated
• Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS) – Corcept Therapeutics, Incorporated
• Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism – Corcept Therapeutics, Incorporated
• Press Releases – Corcept Therapeutics, Incorporated
• Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes – Corcept Therapeutics, Incorporated
• Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update – Corcept Therapeutics, Incorporated
• Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call – Corcept Therapeutics, Incorporated
• Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update – Corcept Therapeutics, Incorporated
• Press Releases – Corcept Therapeutics, Incorporated
• Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call – Corcept Therapeutics, Incorporated
• View more press releases Close

Social media about Corcept Therapeutics

• Corcept Therapeutics on Wikipedia, Google News & Yahoo Finance
• Corcept Therapeutics on LinkedIn, X (Twitter) & YouTube